Literature DB >> 31768758

RAR-Related Orphan Receptor Gamma T (RoRγt)-Related Cytokines Play a Role in Neutrophil Infiltration of the Central Nervous System After Subarachnoid Hemorrhage.

A P Coulibaly1, W T Gartman2, V Swank3, J A Gomes4, L Ruozhuo5, J DeBacker6, J J Provencio7.   

Abstract

BACKGROUND: How inflammatory cells are recruited into the central nervous system is a topic of interest in a number of neurological injuries. In aneurysmal subarachnoid hemorrhage (SAH), neutrophil accumulation in the central nervous system 3 days after the hemorrhage is a critical step in the development of delayed cerebral injury (DCI). The mechanism by which neutrophils enter the central nervous system is still unclear. METHODS AND
RESULTS: To identify human effectors of neutrophil recruitment, cerebrospinal fluid (CSF) samples were taken from a small, selected sample of SAH patients with external ventricular drainage devices (10 patients). Among a battery of CSF cytokines tested 3 days after SAH, five cytokines were associated with poor 90-day outcome (modified Rankin Score 3-6). A parallel study in a mouse model of mild SAH showed elevation in three cytokines in the CNS compared to sham. IL-17 and IL-2 were increased in both patients and the mouse model. IL-17 was investigated further because of its known role in neutrophil recruitment. Inhibition of RAR-Related Orphan Receptor Gamma T, the master transcription factor of IL-17, with the inverse agonist GSK805 suppressed neutrophils entry into the CNS after SAH compared to control. Using an IL-17 reporter mouse, we investigated the source of IL-17 and found that myeloid cells were a common IL-17-producing cell type in the meninges after SAH, suggesting an autocrine role for neutrophil recruitment.
CONCLUSIONS: Taken together, IL-17 appears to be in important factor in the recruitment of neutrophils into the meninges after SAH and could be an important target for therapies to ameliorate DCI.

Entities:  

Keywords:  Delayed cerebral injury; IL-17; Neuroinflammation; Neutrophils; Subarachnoid hemorrhage

Year:  2020        PMID: 31768758      PMCID: PMC7246153          DOI: 10.1007/s12028-019-00871-9

Source DB:  PubMed          Journal:  Neurocrit Care        ISSN: 1541-6933            Impact factor:   3.210


  39 in total

1.  Neutrophil depletion after subarachnoid hemorrhage improves memory via NMDA receptors.

Authors:  Jose Javier Provencio; Valerie Swank; Haiyan Lu; Sylvain Brunet; Selva Baltan; Rohini V Khapre; Himabindu Seerapu; Olga N Kokiko-Cochran; Bruce T Lamb; Richard M Ransohoff
Journal:  Brain Behav Immun       Date:  2016-02-09       Impact factor: 7.217

Review 2.  Aneurysmal subarachnoid hemorrhage.

Authors:  Jose I Suarez; Robert W Tarr; Warren R Selman
Journal:  N Engl J Med       Date:  2006-01-26       Impact factor: 91.245

Review 3.  Subarachnoid hemorrhage and inflammation: bench to bedside and back.

Authors:  J Javier Provencio; Nirav Vora
Journal:  Semin Neurol       Date:  2005-12       Impact factor: 3.420

Review 4.  Cognitive and functional outcome after aneurysmal subarachnoid hemorrhage.

Authors:  Timour Al-Khindi; R Loch Macdonald; Tom A Schweizer
Journal:  Stroke       Date:  2010-07-01       Impact factor: 7.914

5.  Randomised trial of clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid hemorrhage undergoing surgical clipping (CONSCIOUS-2).

Authors:  R Loch Macdonald; Randall T Higashida; Emanuela Keller; Stephan A Mayer; Andy Molyneux; Andreas Raabe; Peter Vajkoczy; Isabel Wanke; Doris Bach; Aline Frey; Angelina Marr; Sébastien Roux; Neal Kassell
Journal:  Acta Neurochir Suppl       Date:  2013

Review 6.  Critical care management of patients following aneurysmal subarachnoid hemorrhage: recommendations from the Neurocritical Care Society's Multidisciplinary Consensus Conference.

Authors:  Michael N Diringer; Thomas P Bleck; J Claude Hemphill; David Menon; Lori Shutter; Paul Vespa; Nicolas Bruder; E Sander Connolly; Giuseppe Citerio; Daryl Gress; Daniel Hänggi; Brian L Hoh; Giuseppe Lanzino; Peter Le Roux; Alejandro Rabinstein; Erich Schmutzhard; Nino Stocchetti; Jose I Suarez; Miriam Treggiari; Ming-Yuan Tseng; Mervyn D I Vergouwen; Stefan Wolf; Gregory Zipfel
Journal:  Neurocrit Care       Date:  2011-09       Impact factor: 3.210

7.  CSF neutrophils are implicated in the development of vasospasm in subarachnoid hemorrhage.

Authors:  J J Provencio; X Fu; A Siu; P A Rasmussen; S L Hazen; R M Ransohoff
Journal:  Neurocrit Care       Date:  2010-04       Impact factor: 3.210

8.  The burden of the systemic inflammatory response predicts vasospasm and outcome after subarachnoid hemorrhage.

Authors:  Rajat Dhar; Michael N Diringer
Journal:  Neurocrit Care       Date:  2008       Impact factor: 3.210

9.  Effectiveness of intrathecal nicardipine on cerebral vasospasm in non-traumatic subarachnoid hemorrhage: a systematic review.

Authors:  Daniel Stuart; Robin Christian; Hartmut Uschmann; Michelle Palokas
Journal:  JBI Database System Rev Implement Rep       Date:  2018-10

10.  Evaluation of cognitive impairment by the Montreal cognitive assessment in patients with aneurysmal subarachnoid haemorrhage: prevalence, risk factors and correlations with 3 month outcomes.

Authors:  George Kwok Chu Wong; Sandy Lam; Karine Ngai; Adrian Wong; Vincent Mok; W S Poon
Journal:  J Neurol Neurosurg Psychiatry       Date:  2012-07-31       Impact factor: 10.154

View more
  2 in total

Review 1.  A Systematic Review of Inflammatory Cytokine Changes Following Aneurysmal Subarachnoid Hemorrhage in Animal Models and Humans.

Authors:  Patrick Devlin; Tauheed Ishrat; Ansley Grimes Stanfill
Journal:  Transl Stroke Res       Date:  2022-03-09       Impact factor: 6.829

2.  Neutrophil Enzyme Myeloperoxidase Modulates Neuronal Response in a Model of Subarachnoid Hemorrhage by Venous Injury.

Authors:  Aminata P Coulibaly; Pinar Pezuk; Paul Varghese; William Gartman; Danielle Triebwasser; Joshua A Kulas; Lei Liu; Mariam Syed; Petr Tvrdik; Heather Ferris; J Javier Provencio
Journal:  Stroke       Date:  2021-08-18       Impact factor: 10.170

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.